Martin-Manso Gema, Hanley Patrick J
Program for Cell Enhancement and Technologies for Immunotherapy, Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA.
Methods Mol Biol. 2015;1283:53-63. doi: 10.1007/7651_2014_164.
Bone marrow-derived human mesenchymal stromal cells (hMSCs) constitute a promising therapeutic approach. However, the extremely low frequency of hMSCs in bone marrow makes the translation of these regulatory cells to clinical therapies difficult for large patient populations. Here, we describe a good manufacturing practices-compliant procedure for the expansion of hMSCs using the Quantum Cell Expansion System. This closed and automated system allows the large-scale expansion of hMSCs while maintaining their multipotency, immunophenotype, morphology, and karyotype.
骨髓来源的人间充质基质细胞（hMSCs）构成了一种很有前景的治疗方法。然而，骨髓中hMSCs的频率极低，这使得将这些调节细胞应用于针对大量患者群体的临床治疗变得困难。在此，我们描述了一种使用量子细胞扩增系统扩增hMSCs的符合药品生产质量管理规范的程序。这种封闭且自动化的系统能够在维持hMSCs的多能性、免疫表型、形态和核型的同时实现其大规模扩增。
